Supplemental Sentinel Lymph Node Decision Curve Data

Published: 18 November 2022| Version 2 | DOI: 10.17632/8t7pc9kfzp.2
Cimarron Sharon, Richard Straker, Phyllis Gimotty, Emily Chu, Tara Mitchell, John Miura, Michael Marchetti, Edmund Bartlett, Giorgos Karakousis


This data is meant to accompany the manuscript published in the Journal of the American Academy of Dermatology, titled "Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: a population-based analysis". This supplemental data contains the multivariable logistic regression models developed to predict 5-year melanoma specific death with and without sentinel lymph node status, and a supplemental table demonstrating the net benefit provided by sentinel lymph node status at each risk threshold probability for melanoma-specific death among the entire study cohort. Figures include: 1) Receiver operating curves of models estimating risk for 5-year melanoma-specific death among patients with stage IIB/C cutaneous melanoma with a) thickness and ulceration alone and b) incorporating sentinel lymph node status. 2) Histogram demonstrating distribution of predicted risk among patients with stage IIB/C cutaneous melanoma based upon the Clinicopathologic-Sentinel Lymph Node model. 3) Decision curve analysis demonstrating added net benefit with inclusion of sentinel lymph node status in estimating risk for 5-year melanoma-specific death compared to a model including thickness and ulceration alone among stage IIB/C cutaneous melanoma patients a) <65 and b) ≥65 years of age.



Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center


Decision Analysis, Melanoma Sentinel Node, Melanoma, Melanoma Surgery, Adjuvant Therapy


SPORE in Skin Cancer

P50 CA 261608